Funding Alert Vol. 31 No. 3 Alert # 2 - March 10, 2020

Texas Department of State Health Services icon Funding Information Center icon Toll free: 1-888-963-7111 ext. 7684 icon Austin phone: 512-776-7684 icon Fax: 512-776-7474


The Texas Department of State Health Services Funding Alert is published weekly.  If you wish to subscribe to the Funding Information Center Funding Alert and other services, please call 512-776-7684 or fill out our online subscription form which can be found at: dshs.texas.gov/fic/subscribe.aspx.  Information in the Funding Alert is not copyrighted and may be reproduced. The Texas Department of State Health Services Funding Information Center would appreciate credit for the material used and a copy of the reprint. For information on viewing Adobe Acrobat .pdf and other files, see file viewing information.

Disclaimer: External links to other sites are intended to be informational and do not have the endorsement of the Department of State Health Services. These sites may also not be accessible to persons with disabilities. External e-mail links are provided to you as a courtesy. Please be advised that you are not e-mailing the Texas Department of State Health Services (DSHS) and DSHS policies do not apply should you choose to correspond.


Funding News and Grant Tips

Texas Women's Foundation Creates Gendered Impact Portfolio
The Dallas-based Texas Women's Foundation has announced that 100 percent of its financial assets are now invested in a 100 percent gendered impact portfolio designed to yield both strong financial returns and social benefits for women and girls.
According to the foundation, it is the first and, to date, only women's fund or foundation to move all its assets — endowments, operating investments, and donor-advised funds — into a gendered impact portfolio aligned with its mission. Managed by the Chicago office of Graystone Consulting, a business of Morgan Stanley, the portfolio is fully diversified across asset classes, and every fund is evaluated against its particular financial benchmarks as well as gendered impact, as measured by manager activation and its focus on one or more of the United Nations Sustainable Development Goals related to women and girls.
From the Foundation Center’s Philanthropy News Digest News web site, accessed 3/4/20icon

Jack Ma Foundation Awards $2.15 Million for Coronavirus Vaccine
The Jack Ma Foundation has announced a $2.15 million grant to the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia, to accelerate the development of a coronavirus vaccine.
A joint venture between the University of Melbourne and Royal Melbourne Hospital, the institute will use the grant to support efforts in three areas: development of an active vaccine platform that stimulates the body to produce antibodies to attack the virus; development of a passive platform for the direct transfer of antibodies to a non-immune individual; and efforts to ensure the efficacy, safety, and readiness of the vaccine for phase-one human trials. In January, the institute's scientists became the first to successfully grow the novel coronavirus in laboratory cell culture outside China.
The grant is part of a $14.4 million commitment announced by the foundation in January in support of efforts to develop a coronavirus vaccine; in February, the foundation awarded a $2.1 million grant to Columbia University.
From the Foundation Center’s Philanthropy News Digest News web site, accessed 3/4/20icon


Public Funding Opportunities

Department of Defense (DoD) Autism, Clinical Translational Research Award: W81XWH-20-ARP-CTRA
SOURCE: Department of Defense (DoD)
APPLICATION DEADLINE: Pre-Application Submission Deadline: 4/15/20. After an initial review, selected applicants will be invited to submit a full proposal by 7/16/20.
$AVAILABLE: Please see URL for funding information.
ELIGIBILITY: Unrestricted -- open to any type of entity.
PURPOSE: This award is intended to support early-phase, proof-of-principle translational studies that will examine hypothesis-based, innovative interventions/clinical research that has the potential to address current clinical deficits for Autism Spectrum Disorders (ASD). Applications are strongly encouraged to address one of the FY20 ARP Clinical Translational Research Award Areas of Interest. If the proposed project does not address any of the FY20 ARP Clinical Translational Research Award Areas of Interest, the application should describe how the project will nevertheless address a critical need of the ASD community. Outcomes from studies funded by this award are anticipated to provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform ASD clinical care.
CFDA: 12.420
CONTACT: CDMRP Help Desk, (301) 682-5507, email: help@eBRAP.org. For more information see https://www.grants.gov/web/grants/view-opportunity.html?oppId=324917
From Grants.gov web site, accessed 3/6/20icon
subject(s) medical research, mental health

Department of Defense (DoD) Autism, Idea Development Award: W81XWH-20-ARP-IDA
SOURCE: Department of Defense (DoD)
APPLICATION DEADLINE: Pre-Application Submission Deadline: 4/15/20. After an initial review, selected applicants will be invited to submit a full proposal by 7/16/20.
$ AVAILABLE: Please see URL for funding information.
ELIGIBILITY: Unrestricted -- open to any type of entity.
PURPOSE: The Autism Research Program (ARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with ASD. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.
The FY20 ARP Idea Development Award seeks applications from all areas of research. 
CFDA: 12.420 
CONTACT: CDMRP Help Desk, (301) 682-5507, email: help@eBRAP.org. For more information see https://www.grants.gov/web/grants/view-opportunity.html?oppId=324901
From Grants.gov web site accessed, 3/6/20icon
Subject(s) medical research, mental health

Peer Reviewed Medical Research Program Focused Program Award: W81XWH-20-PRMRP-FPA
SOURCE: Department of Defense (DoD)
APPLICATION DEADLINE: Pre-Application Submission Deadline: 4/23/20. After an initial review, selected applicants will be invited to submit a full proposal by 8/6/20.
$ AVAILABLE: Please see URL for funding information.
ELIGIBILITY: Unrestricted -- open to any type of entity.
PURPOSE: Applications to the Fiscal Year 2020 (FY20) Peer Reviewed Medical Research Program (PRMRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The PRMRP was initiated in 1999 to provide medical research projects of clear scientific merit and direct relevance to military health. Appropriations for the PRMRP from FY99 through FY19 totaled $2.35 billion (B). The FY20 appropriation is $360 million (M). The vision of the FY20 PRMRP is to improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries, and its mission is to encourage, identify, select, and manage medical research projects of clear scientific merit and direct relevance to military health. The PRMRP challenges the scientific and clinical communities to address the FY20 PRMRP Topic Areas with original ideas that foster new directions along the entire spectrum of research and clinical care. The program seeks applications in laboratory, clinical, behavioral, epidemiological, and other areas of research to advance knowledge in disease etiology, improve prevention, detection, diagnosis, treatment, and quality of life for those affected by a relevant disease or condition. 
CFDA: 12.420 
CONTACT: CDMRP Help Desk, (301) 682-5507, email: help@eBRAP.org. For more information see https://www.grants.gov/web/grants/view-opportunity.html?oppId=324964
From Grants.gov web site accessed, 3/6/20icon
Subject(s) medical research

Research to Support the Reduction and Elimination of Mental Health Disparities (Admin Supp Clinical Trial Optional) Reissue of PA-17-165: PA-18-621
SOURCE: National Institutes of Health (NIH)
APPLICATION DEADLINE: 6/1/20.
$ AVAILABLE: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
ELIGIBILITY: * Public/state/private controlled institutions of higher education.
* Hispanic-serving institutions.
* Historically Black Colleges and Universities (HBCUs).
* Tribally Controlled Colleges and Universities (TCCUs).
* Alaska native and native Hawaiian serving institutions.
* Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
* Nonprofits with or without 501(c)(3) IRS status (other than institutions of higher education).
* Small businesses.
* For-profit organizations (other than small businesses).
* State governments.
* County governments.
* City or township governments.
* Special district governments.
* Indian/Native American tribal governments (federally recognized and other than federally recognized).
* Eligible agencies of the federal government.
* U.S. territories or possessions.
* Independent school districts.
* Public housing authorities/Indian housing authorities.
* Native American tribal organizations (other than federally recognized tribal governments).
* Faith-based or community-based organizations.
* Regional organizations.
PURPOSE: The purpose of this FOA is to support Administrative Supplements to active NIMH grants to foster research across the NIMH Strategic Objectives that target the reduction and elimination of mental health disparities by race and ethnicity, geography, and socioeconomic status in the United States. This initiative aims to generate research within the scientific scope of the parent grant that identifies mechanisms underlying disparities or differences in mental health status and/or enhances optimal delivery of mental health interventions among diverse groups.
CFDA: 93.242
CONTACT: Please see URL for contact information. For more information see https://www.grants.gov/web/grants/view-opportunity.html?oppId=300438
From Grants.gov web site accessed, 3/6/20icon
Subject(s) medical research, mental health, health disparities

Rural Community Development Initiative (RCDI): USDA-RD-HCFP-RCDI-2020
SOURCE: U.S. Department of Agriculture (USDA)
APPLICATION DEADLINE: 5/13/20.
$ AVAILABLE: Grants of up to $250,000. Applicants must provide matching funds in an amount at least equal to the Federal grant.
ELIGIBILITY: Qualified private, nonprofit and public (including tribal) intermediary organizations. Definitions that describe eligible organizations can be found in the full announcement: https://www.rd.usda.gov/programs-services/rural-community-development-initiative-grants.
PURPOSE: These grants will be made to help nonprofit housing and community development intermediary organizations support housing, community facilities, and community and economic development projects in rural areas. Priority will be given to applications that address USDA's goal to reduce the morbidity and mortality associated with Substance Use Disorder (including opioid misuse) in high-risk rural communities.
CFDA: 10.446
CONTACT: Texas Contact: Michael B. Canales, Texas State Office, Federal Building, Suite 102, 101 South Main, Temple, TX 76501, (254) 742-9787, TDD (254) 742-9749.
From Federal Register, p12761, 3/4/20icon
Subject(s) housing/homeless, rural health, substance abuse

Strengthening the Impact of Community Health Workers on the HIV Care Continuum in the US (R01 Clinical Trial Optional): RFA-NR-20-002
SOURCE: National Institutes of Health (NIH)
APPLICATION DEADLINE: 5/13/20.
$ AVAILABLE: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
ELIGIBILITY: * Public/state/private controlled institutions of higher education.
* Hispanic-serving institutions.
* Historically Black Colleges and Universities (HBCUs).
* Tribally Controlled Colleges and Universities (TCCUs).
* Alaska native and native Hawaiian serving institutions.
* Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
* Nonprofits with or without 501(c)(3) IRS status (other than institutions of higher education).
* Small businesses.
* For-profit organizations (other than small businesses).
* State governments.
* County governments.
* City or township governments.
* Special district governments.
* Indian/Native American tribal governments (federally recognized and other than federally recognized).
* Eligible agencies of the federal government.
* U.S. territories or possessions.
* Independent school districts.
* Public housing authorities/Indian housing authorities.
* Native American tribal organizations (other than federally recognized tribal governments).
* Faith-based or community-based organizations.
* Regional organizations.
PURPOSE: The purpose of this award is to promote research on the use of community health workers (CHW) to improve the HIV care continuum in the United States. The RFA will support research on the effectiveness of scalable tools, trainings, and strategies designed to strengthen the ability of CHW to improve HIV care among people living with HIV (PLH). Research applications must incorporate a patient outcome related to the HIV care continuum, such as care engagement, antiretroviral adherence, or viral suppression. Effectiveness research that identifies the mediators and mechanisms through which CHW make an impact is also encouraged.
CFDA: 93.361
CONTACT: Please see URL for contact information. For more information see https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-20-002.html
From Grants.gov web site, accessed 3/4/20icon
Subject(s) HIV/AIDS research

Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed): PAR-20-116
SOURCE: National Institutes of Health (NIH), National Cancer Institute (NCI)
APPLICATION DEADLINE: 5/21/2020; 11/19/20; 5/20/21; 11/18/21.
$ AVAILABLE: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Please see full announcement for funding information.
ELIGIBILITY: *Public/state/private controlled institutions of higher education.
* Hispanic-serving institutions.
* Historically Black Colleges and Universities (HBCUs).
* Tribally Controlled Colleges and Universities (TCCUs).
* Alaska native and native Hawaiian serving institutions.
* Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
* Nonprofits with or without 501(c)(3) IRS status (other than institutions of higher education).
* Small businesses.
* For-profit organizations (other than small businesses).
* State governments.
* County governments.
* City or township governments.
* Special district governments.
* Indian/Native American tribal governments (federally recognized and other than federally recognized).
* Eligible agencies of the federal government.
* U.S. territories or possessions.
* Independent school districts.
* Public housing authorities/Indian housing authorities.
* Native American tribal organizations (other than federally recognized tribal governments).
* Faith-based or community-based organizations.
* Regional organizations.
PURPOSE: This Funding Opportunity Announcement (FOA) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
CFDA: 93.394; 93.395
CONTACT: Please see URL for contact information. For more information see https://www.grants.gov/web/grants/view-opportunity.html?oppId=324794
From Grants.gov web site, accessed 3/4/20icon
Subject(s) cancer research


Private Funding Opportunities

Alzheimer's Drug Discovery Foundation Invites Applications for Clinical Trials, Epidemiological Studies
SOURCE: Alzheimer’s Drug Discovery Foundation (ADDF)
APPLICATION DEADLINE: Letters of Intent: 4/10/20. Upon review, selected applicants will be invited to submit a full proposal by 5/8/20.
$ AVAILABLE: Grants of up to $100,000 over a year will be awarded in support of epidemiological analysis and grants of up to $3 million over a variable number of years will be awarded for clinical trials. 
ELIGIBILITY: Eligible applicants include researchers and clinicians at academic medical centers, universities, nonprofits, and biotechnology companies worldwide. Existing companies and new startups also are eligible, and industry partnerships are strongly encouraged.
PURPOSE: Funding priorities identified by the foundation include:
Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) — Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, ADDF will support collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script.
Comparative Effectiveness Research — For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. ADDF will consider funding research that generates an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect individuals from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology.
Cognitive Decline and Cognitive Reserve — Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.
Contact: Please see URL for contact information. For more information see https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline
From The Foundation Center’s Philanthropy News Digest web site, accessed 3/4/20icon
Subjects(s) medical research

Foundation for Women's Wellness Accepting Applications for Research Projects - Research Awards
SOURCE: Foundation for Women's Wellness (FWW)
APPLICATION DEADLINE: 4/6/20.
$ AVAILABLE: Awards are one-time, non-recurring grants of $25,000.
ELIGIBILITY: Only one application per principal investigator (PI). There is no limit to the number of applications from any one medical institution/organization. 
PURPOSE: Awards target small, short-term studies with promise for improving medical care in leading women’s health concerns including cardiovascular disease, female cancers, the role of hormones in disease and stage-of-life health issues like pregnancy and menopause and diseases disproportionately affecting women.
CONTACT: Please see URL for contact information. For more information see http://thefww.org/research-awards/
From The Foundation Center’s Philanthropy News Digest web site, accessed 3/4/20icon
Subject(s) medical research, women's health

Muscular Dystrophy Association Invites Applications for Clinical Research
SOURCE: Muscular Dystrophy Association (MDA)
APPLICATION DEADLINE: Letter of intent: 4/1/20. Application: Upon review, selected applicants will be invited to submit a full proposal by 8/1/20.
$AVAILABLE: Grants of up to three years in duration for up to $500,000. 
ELIGIBILITY: Eligible candidates must hold an MD, PhD, DSc, or equivalent degree (i.e., DO) and be a professional or faculty member (professor, associate professor, or assistant professor) at an appropriate educational, medical, or research institution.
PURPOSE: Clinical Research Grants are designed to support observational studies such as natural history, biomarker, and outcome measure studies. Clinical trials of compounds already on the market performed at academic medical centers may also be considered. Trials of novel therapeutics should be submitted as MDA Venture Philanthropy (MVP) projects. MVP commonly supports for-profit entities and return-on-investment is negotiated by MDA.
Clinical Research Grants may last up to three years and are milestone-driven, with funds released according to completion of pre-agreed upon sections of the project. Clinical Research Grants may last up to three years and are milestone-driven, with funds released according to completion of pre-agreed upon sections of the project. The maximum budget for these awards is $500,000 total over one to three years. 
CONTACT: Please see URL for contact information. For more information see https://www.mda.org/science/funding-opportunities
The Foundation Center's Philanthropy News Digest web site, accessed 3/6/20icon
Subject(s) medical research

Muscular Dystrophy Association Invites Applications for Research Infrastructure Grants
SOURCE: Muscular Dystrophy Association (MDA)
APPLICATION DEADLINE: Letter of intent: 4/1/20. Application: Upon review, selected applicants will be invited to submit a full proposal by 8/1/20. 
$ AVAILABLE: Grants of up to three years in duration for up to $300,000.
ELIGIBILITY: To be eligible, applicants must hold an MD, PhD, DSc, or equivalent degree (i.e. DO) and be a professional or faculty member (professor, associate professor, or assistant professor) at an appropriate educational, medical, corporate, or research institution.
PURPOSE: Grants will be awarded in support of infrastructure that helps further research for the purpose of therapy development. Infrastructure grants may be used for the development of tools, techniques, and services such as tissue banks to support the collection and storage of patient tissue for research purposes; antibody banks; the development of core facilities (e.g., sequencing/phenotyping cores, vector production); and Web-based databases. 
CONTACT: Please see URL for contact information. For more information see https://www.mda.org/science/funding-opportunities
From The Foundation Center's Philanthropy News Digest web site, accessed 3/4/20icon
Subject(s) medical research


Events

Webinar - Quest for Grants Training Series: Grant Writing Best Practices
SPONSOR: Harris County Department of Education, Center for Grants Development 
WHEN: April 8, 1:30 to 3 pm.
WHERE: Webinar.
DESCRIPTION: Please see URL for description.
COST: In Harris County: $25. Outside Harris County: $45. For more information and registration go to https://hcde-texas.org/workshop-registration/
CONTACT: Iliana Gonzalez, (713) 696-1393, email: igonzalez@hcde-texas.org.
From Harris County Department of Education email, 3/4/20icon

Refining Your Leadership Approach and Style: Understand, Strengthen and Adapt Your Personal Leadership Style (In-Person)
SPONSOR: Texas Executive Education, The University of Texas at Austin
WHEN: April 6-10. Registration begins at 8:00 a.m. and class runs 8:30 – 4:30 each day with a one hour networking lunch included. During the week you will travel to an onsite location for an experiential leadership exercise.
WHERE: The University of Texas at Austin, Rowling Hall, 300 W Martin Luther King Jr Blvd., (Austin, TX).
DESCRIPTION: Grow as a leader. Identify, optimize and adapt your personal leadership style. Strengthen your leadership ability through a combination of classroom instruction in leadership concepts and frameworks, assessments,
peer discussion, and outdoor experiential exercises, which will result in personal reflection, learning and action planning. Achieve awareness and mastery of your own leadership approaches and expertise. Improve your
understanding of contextual demands and how divergent leadership styles and behaviors best meet those demands. Draw out personal learning based on tangible opportunities to practice the art of leadership.
COST: $6,600. For more information and registration see https://www.mccombs.utexas.edu/execed/take-a-class/leadership-management/refining-your-leadership-approach-and-style
CONTACT: Texas Executive Education, (512) 471-5893, email: execed@mccombs.utexas.edu.
From Texas Executive Education web site, accessed 3/6/20icon

Decision Quality: Make the Right Choice Every Time (In-Person)
SPONSOR: Texas Executive Education, The University of Texas at Austin
WHEN: April 20-21. Registration begins at 8:00 a.m. and class runs 8:30 – 4:30 both days with a one-hour networking lunch included.
WHERE: AT&T Executive Education & Conference Center 1900 University Avenue (Austin, TX).
DESCRIPTION: Learn how to frame strategic choices, generate alternatives, develop credible forecasts, quantify uncertainty and judge the quality of a decision at the time it is made. You make decisions every day that affect your success. Leveraging an appropriate framework allows you to define the requirements of a quality decision and embrace uncertainty to your advantage. Collaborate in an interactive team environment on a complex decision, applying tools and techniques to a practical situation.
COST: $2,950. For more information and registration see https://www.mccombs.utexas.edu/execed/take-a-class/strategic-decision-and-risk-management/decision-quality--make-the-right-choice-every-time
CONTACT: Texas Executive Education, (512) 471-5893, email: execed@mccombs.utexas.edu.
From Texas Executive Education web site, accessed 3/6/20icon


returnReturn to Alert

Last updated July 3, 2020